Table 3.
Baseline characteristics of statin users and non-users in patients with no comorbidity (based on Charlson Comorbidity Score28)
| Statinusers (n =6113) | Non-users (n =27400) | p-value | |
|---|---|---|---|
| Age in years: mean ± SD | 56.6 ± 12.1 | 43.6 ± 10.3 | < 0.0001 |
| Male gender: n (%) | 3707 (60.6) | 12246 (44.7) | < 0.0001 |
| Charlson Comorbidity total score: mean ± SD | 0 ± 0 | 0 ± 0 | |
| Psychological disorders at baseline *: n (%) | 789 (12.9) | 2802 (10.2) | < 0.0001 |
| Illicit drug use: n (%) | 6 (0.1) | 40 (0.1) | 0.45 |
| Alcohol abuse/dependence: n (%) | 48 (0.8) | 153 (0.6) | 0.04 |
| Smoking: n (%) | 477 (7.8) | 1401 (5.1) | < 0.0001 |
| Obesity: n (%) | 901 (14.7) | 2520 (9.2) | < 0.0001 |
| Vision defects/blindness | 2613 (42.7) | 11048 (40.3) | 0.001 |
| Number of outpatient medical encounters during baseline period: mean ± SD | 27.2 ± 25.4 | 19.4 ± 21 | < 0.0001 |
| Number of inpatient admissions during baseline period: mean ± SD | 0.18 ± 0.5 | 0.13 ± 0.4 | < 0.0001 |
| Number of outpatient medical encounters during follow-up period: mean ± SD | 81.1 ± 78.3 | 55.6 ± 59.6 | < 0.0001 |
| Number of inpatient admissions during follow-up period: mean ± SD | 2.1 ± 1.9 | 1.7 ± 1.5 | < 0.0001 |
| Medications: | |||
| Beta-blocker: n (%) | 1385 (22.7) | 1500 (5.5) | < 0.0001 |
| Diuretic: n (%) | 1748 (28.6) | 2305 (8.4) | < 0.0001 |
| Calcium channel Blocker: n (%) | 1092 (17.9) | 1064 (3.9) | < 0.0001 |
| Non-statin lipid lowering drugs: n (%) | 755(12.4) | 360 (1.3) | < 0.0001 |
| ACE/ARB: n (%) | 2371 (38.8) | 2265 (8.3) | < 0.0001 |
| Oral hypoglycemic: n (%) | 32 (0.5) | 89 (0.3) | 0.02 |
| Cytochrome p 450: n (%) | 465 (7.6) | 1113 (4.1) | < 0.0001 |
| Aspirin: n (%) | 2434 (39.8) | 1761 (6.4) | < 0.0001 |
| NSAID: n (%) | 3550 (58.1) | 16860 (61.5) | < 0.0001 |
| SSRI: n (%) | 944 (15.4) | 3256 (11.9) | < 0.0001 |
| Systemic corticosteroid: n (%) | 127 (2.1) | 873 (3.2) | < 0.0001 |
| Antipsychotic: n (%) | 62 (1.0) | 232 (0.8) | 0.2 |
| Sedatives: n (%) | 1094 (17.9) | 4182 (15.3) | < 0.0001 |
| Tricyclic antidepressants: n (%) | 11 (0.2) | 42 (0.2) | 0.4 |
ACE/ARB: Angiotensin-receptor blockers & angiotensin converting enzyme inhibitors; NSAID: non-steroidal anti-inflammatory drugs; Cytochrome p 450: medications that inhibit the Cytochrome p450 system as identified in a recent FDA warning; 29 SSRI: selective serotonin reuptake inhibitors
*
Schizophrenia/other psychosis, mood disorders, depression, and bipolar disorder as detailed in Appendix 1